2008年转移性胰腺癌治疗方面的成就。
Accomplishments in 2008 in the treatment of metastatic pancreatic cancer.
作者信息
Heinemann Volker, Philip Philip A, Pelzer Uwe
机构信息
Department of Medical Oncology, Ludwig-Maximilian-University of Munich, Munich, Germany.
出版信息
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S43-7.
Abstract
Overview of the DiseaseIncidencePrognosisCurrent Treatment StandardsCytotoxic TherapyTargeted TherapySalvage TherapyAccomplishments or Lack of AccomplishmentsTherapySalvage TherapyBiomarkersApplication of the AccomplishmentsFuture DirectionsCurrent Basic ResearchOngoing Clinical StudiesMajor Obstacles to Progress in Drug DevelopmentGemcitabine PlatformChoice of Molecular TargetsPatient Selection.
摘要
疾病概述
发病率
预后
当前治疗标准
细胞毒性疗法
靶向疗法
挽救疗法
成就或缺乏成就
疗法
挽救疗法
生物标志物
成就的应用
未来方向
当前基础研究
正在进行的临床研究
药物开发进展的主要障碍
吉西他滨平台
分子靶点的选择
患者选择
相似文献
1
Accomplishments in 2008 in the treatment of metastatic pancreatic cancer.
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S43-7.
2
Accomplishments in 2007 in the treatment of metastatic pancreatic cancer.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S37-41.
3
Accomplishments in 2007 in the management of curable metastatic colorectal cancer.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S13-8.
4
Accomplishments in 2007 in the adjuvant treatment of colorectal cancer.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S2-6.
5
Accomplishments in 2008 in the management of localized pancreatic cancer.
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S37-42.
6
Accomplishments in 2007 in the management of localized pancreatic cancer.
Gastrointest Cancer Res. 2008 May;2(3 Suppl):S32-6.
7
Accomplishments in 2008 in the management of esophageal cancer.
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S53-7.
8
Accomplishments in 2008 in the management of localized gastric cancer.
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S48-52.
9
Metastatic Pancreatic Cancer: Where Are We?
Oncol Rev. 2024 Jan 18;17:11364. doi: 10.3389/or.2023.11364. eCollection 2023.
10
Monoclonal antibodies in cancer treatment: a review of recent progress.
BioDrugs. 1999 Sep;12(3):209-36. doi: 10.2165/00063030-199912030-00004.
引用本文的文献
1
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.
BMC Cancer. 2014 Mar 19;14:204. doi: 10.1186/1471-2407-14-204.
2
Therapeutic antibodies for the treatment of pancreatic cancer.
ScientificWorldJournal. 2010 Jun 15;10:1107-20. doi: 10.1100/tsw.2010.103.
本文引用的文献
1
Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.
Clin Exp Metastasis. 2009;26(7):611-23. doi: 10.1007/s10585-009-9260-0. Epub 2009 May 7.
2
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
J Clin Oncol. 2009 May 1;27(13):2231-7. doi: 10.1200/JCO.2008.20.0238. Epub 2009 Mar 23.
3
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials.
Br J Cancer. 2009 Jan 27;100(2):246-50. doi: 10.1038/sj.bjc.6604838. Epub 2009 Jan 6.
4
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Gastroenterology. 2009 Jan;136(1):187-95. doi: 10.1053/j.gastro.2008.09.067. Epub 2008 Oct 7.
5
Perioperative management of pancreatic cancer.
Ann Oncol. 2008 Sep;19 Suppl 7:vii273-8. doi: 10.1093/annonc/mdn450.
6
An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.
Mol Cancer Ther. 2008 Sep;7(9):2725-35. doi: 10.1158/1535-7163.MCT-08-0573.
7
Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma.
Pancreas. 2009 Jan;38(1):e1-6. doi: 10.1097/MPA.0b013e3181878b7f.
8
Pancreatic cancer stem cells.
J Clin Oncol. 2008 Jun 10;26(17):2806-12. doi: 10.1200/JCO.2008.16.6702.
9
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
Lancet. 2008 Jun 21;371(9630):2101-8. doi: 10.1016/S0140-6736(08)60661-3. Epub 2008 May 29.
10
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.
EMBO Rep. 2008 Jun;9(6):582-9. doi: 10.1038/embor.2008.74. Epub 2008 May 16.
Zotero 插件